Tauriga Sciences, Inc. Generates Record Monthly E-Commerce Sales for the Month of June 2020
01 July 2020 - 10:21PM
InvestorsHub NewsWire
The Company has Easily Surpassed its Previous
Monthly Record, of $20,301.93 in E-Commerce Sales, Posted During
May 2020
NEW YORK, NY -- July 1, 2020 -- InvestorsHub
NewsWire -- Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating, diversified
life sciences Company, with a proprietary line of functional
“supplement” chewing gums (Flavors: Pomegranate, Blood Orange,
Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two
ongoing Biotechnology initiatives, today announced that its highest
margin business segment (E-Commerce), continues to demonstrate
accelerating levels of growth, momentum, and overall
strength. For the month of June 2020, the Company has
established a new monthly record – with respect to its E-Commerce
sales. The Company is confident that its existing fulfillment
infrastructure can handle substantial levels of additional growth,
should that occur. Additionally, the Company maintains robust
levels of inventory on hand, for all of its products and product
lines (fully paid for). Estimated Retail Value of
Inventory on Hand: $700,000 -
$800,000.
For the 4thconsecutive month, the
Company has generated record monthly E-Commerce sales. With
the anticipated availability of all 6 versions of Tauri-Gum™, next
quarter (period: July 1, 2020 – September 30, 2020), the Company is
confident that it will continue to grow its highest margin business
segment.
On a Quarter to Quarter sequential basis, the
Company is pleased to report that its E-Commerce revenue growth was
in the Triple Digits (140%+). This relates to its most
recent completed Quarter – 1stFiscal Quarter of 2021
(Period: April 1, 2020 – June 30, 2020) vs. 4thFiscal
Quarter of 2020 (Period: January 1, 2020 – March 31,
2020).
The gross margins, pertaining to the Company’s
E-Commerce business segment, are consistently greater than
60%.
ABOUT TAURIGA SCIENCES
INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and initiatives. The
company manufactures and distributes several proprietary retail
products and product lines, mainly focused on the Cannabidiol
(“CBD”) and Cannabigerol (“CBG”) Edibles market
segment. The main product line, branded as Tauri-Gum™,
consists of a proprietary supplement chewing gum that is both
Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™
Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused
Tauri-Gum™ Flavor: Peach-Lemon). The Company’s
commercialization strategy consists of a broad array of retail
customers, distributors, and a fast-growing E-Commerce business
segment (E-Commerce website: www.taurigum.com). Please
visit our corporate website, for additional information, as well as
inquiries, at www.tauriga.com
Complementary to the Company’s retail business, are
its two ongoing biotechnology initiatives. The first one
relates to the development of a Pharmaceutical grade version of
Tauri-Gum™, for nausea regulation (specifically designed to help
patients that are subjected to ongoing chemotherapy
treatment). On March 18, 2020, the Company announced that it
filed a provisional U.S. patent application covering its
pharmaceutical grade version of Tauri-Gum™. The Patent, filed
with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS
OF MANUFACTURING, AND METHODS OF TREATMENT”. The second one
relates to a collaboration agreement with Aegea Biotechnologies
Inc. for the co-development of a rapid, multiplexed, Novel
Coronavirus (COVID-19) test with superior sensitivity and
selectivity.
The Company is headquartered in New York City and
operates a regional office in Barcelona, Spain. In addition,
the Company operates a full time E-Commerce fulfillment center
located in LaGrangeville, New York.
DISCLAIMER -- Forward-Looking
Statements
This press release contains certain
“forward-looking statements” as defined by the Private Securities
Litigation Reform Act of 1995 which represent management’s beliefs
and assumptions concerning future events. These forward-looking
statements are often indicated by using words such as “may,”
“will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or
plans, and may include statements regarding corporate objectives as
well as the attainment of certain corporate goals and milestones.
Forward-looking statements are based on present circumstances and
on management’s present beliefs with respect to events that have
not occurred, that may not occur, or that may occur with different
consequences or timing than those now assumed or anticipated.
Actual results may differ materially from those expressed
in forward looking statements due to known and unknown
risks and uncertainties, such as are not guarantees of general
economic and business conditions, the ability to successfully
develop and market products, consumer and business consumption
habits, the ability to consummate successful acquisition and
licensing transactions, fluctuations in exchange rates, and other
factors over which Tauriga has little or no control. Many of these
risks and uncertainties are discussed in greater detail in the
“Risk Factors” section of Tauriga’s Form 10-K and other filings
made from time to time with the Securities and Exchange Commission.
Such forward-looking statements are made only as of the date of
this release, and Tauriga assumes no obligation to update
forward-looking statements to reflect subsequent events or
circumstances. You should not place undue reliance on these
forward-looking statements.
Contact:
CONTACT INFORMATION
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram: @taurigum
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2024 to May 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From May 2023 to May 2024